JP2023523584A5 - - Google Patents
Info
- Publication number
- JP2023523584A5 JP2023523584A5 JP2022564276A JP2022564276A JP2023523584A5 JP 2023523584 A5 JP2023523584 A5 JP 2023523584A5 JP 2022564276 A JP2022564276 A JP 2022564276A JP 2022564276 A JP2022564276 A JP 2022564276A JP 2023523584 A5 JP2023523584 A5 JP 2023523584A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- cancer
- seq
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063015149P | 2020-04-24 | 2020-04-24 | |
| US63/015,149 | 2020-04-24 | ||
| PCT/US2021/028798 WO2021216972A1 (en) | 2020-04-24 | 2021-04-23 | Anti-cd3 antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023523584A JP2023523584A (ja) | 2023-06-06 |
| JP2023523584A5 true JP2023523584A5 (https=) | 2024-05-02 |
| JP7791836B2 JP7791836B2 (ja) | 2025-12-24 |
Family
ID=78270196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022564276A Active JP7791836B2 (ja) | 2020-04-24 | 2021-04-23 | 抗ｃｄ３抗体及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230212289A1 (https=) |
| EP (1) | EP4139347A4 (https=) |
| JP (1) | JP7791836B2 (https=) |
| CN (1) | CN115803340A (https=) |
| CA (1) | CA3176391A1 (https=) |
| WO (1) | WO2021216972A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| MX2023010541A (es) | 2021-03-09 | 2023-11-24 | Cdr Life Ag | Proteinas de union al antigeno del peptido del mhc mage-a4. |
| US12435444B2 (en) | 2021-03-09 | 2025-10-07 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| TWI877602B (zh) * | 2022-04-21 | 2025-03-21 | 中央研究院 | 用於延長壽命及／或治療癌症的經基因工程化先天淋巴細胞 |
| CA3264030A1 (en) * | 2022-08-04 | 2024-02-08 | Memorial Hospital For Cancer And Allied Diseases | Anti-CD24 antibodies and their uses |
| CA3264474A1 (en) | 2022-09-14 | 2024-03-21 | Cdr-Life Ag | MAGE-A4 DOUBLE T LYMPHOCYTE ENGAGEMENT |
| EP4688832A1 (en) * | 2023-03-29 | 2026-02-11 | Nanjing GenScript Biotech Co., Ltd. | Antibodies and variants thereof against human cluster of differentiation 3 protein |
| CN116574182B (zh) * | 2023-06-09 | 2024-02-06 | 上海交通大学医学院附属第九人民医院 | 一种抗人Ki-67抗体及其制备方法和用途 |
| CN121293363B (zh) * | 2025-12-09 | 2026-04-21 | 上海玄言生物科技有限公司 | 一种靶向cd14和cd3的双功能t细胞衔接器及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2121756A4 (en) * | 2006-12-20 | 2011-08-31 | Mmrglobal Inc | ANTIBODIES AND PROCESS FOR THEIR PREPARATION AND USE |
| CN102796199A (zh) * | 2011-05-26 | 2012-11-28 | 中国医学科学院血液病医院 | 抗CD3抗体Fv片段与白介素3融合蛋白突变体、制备方法及其用途 |
| EP2892924B1 (en) * | 2012-06-14 | 2020-11-25 | Therapix Biosciences Ltd. | Humanized antibodies to cluster of differentiation 3 (cd3) |
| CN103173478B (zh) * | 2013-03-04 | 2015-09-09 | 西北大学 | 一种携带ptd的抗人cd3单链抗体的制备方法 |
| CN103467605B (zh) * | 2013-09-05 | 2015-02-04 | 武汉友芝友生物制药有限公司 | 一种cd3抗原及其制备方法和用途 |
| RU2016132863A (ru) * | 2014-01-15 | 2018-02-20 | Займворкс Инк. | БИСПЕЦИФИЧЕСКИЕ CD3 и CD19 АНТИГЕНСВЯЗЫВАЮЩИЕ КОНСТРУКЦИИ |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| RU2726446C2 (ru) * | 2014-11-24 | 2020-07-14 | Регенерон Фармасьютикалз, Инк. | Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3 |
| US11046768B2 (en) | 2017-01-27 | 2021-06-29 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| EA201992546A1 (ru) * | 2017-04-24 | 2020-03-06 | Мемориал Слоан Кеттеринг Кэнсер Сентер | Средства на основе антител к cd33 |
| CN111093702A (zh) * | 2017-06-22 | 2020-05-01 | 财团法人生物技术开发中心 | 靶细胞依赖性T细胞的接合和活化型不对称异二聚Fc-ScFv融合抗体形式用于癌症治疗 |
| PE20201265A1 (es) * | 2018-03-21 | 2020-11-19 | Alx Oncology Inc | Anticuerpos contra proteina alfa reguladora de senal y metodos de uso |
| EP3802595A1 (en) * | 2018-06-07 | 2021-04-14 | OncoOne Research & Development GmbH | Anti-oxmif/anti-cd3 antibody for cancer treatment |
| CN110964114B (zh) | 2018-09-29 | 2023-07-04 | 上海博槿生物科技有限公司 | 一种双靶点抗原结合分子 |
| JP2022508529A (ja) | 2018-09-29 | 2022-01-19 | 上海博槿生物科技有限公司 | 二重標的抗原結合分子 |
-
2021
- 2021-04-23 EP EP21792369.7A patent/EP4139347A4/en active Pending
- 2021-04-23 JP JP2022564276A patent/JP7791836B2/ja active Active
- 2021-04-23 CN CN202180043797.1A patent/CN115803340A/zh active Pending
- 2021-04-23 WO PCT/US2021/028798 patent/WO2021216972A1/en not_active Ceased
- 2021-04-23 CA CA3176391A patent/CA3176391A1/en active Pending
- 2021-04-23 US US17/920,539 patent/US20230212289A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023523584A5 (https=) | ||
| Wei et al. | ImmunoPET: concept, design, and applications | |
| Paul et al. | Cancer therapy with antibodies | |
| JP2022546572A5 (https=) | ||
| JP7235904B2 (ja) | 抗ｉｌ１－ｒａｐ抗体 | |
| JP2024530166A5 (https=) | ||
| Mandikian et al. | Relative target affinities of T-cell–dependent bispecific antibodies determine biodistribution in a solid tumor mouse model | |
| Moek et al. | Theranostics using antibodies and antibody-related therapeutics | |
| Lamberts et al. | Antibody positron emission tomography imaging in anticancer drug development | |
| Bacac et al. | A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors | |
| Welt et al. | Phase I study of anticolon cancer humanized antibody A33 | |
| De Pauw et al. | Current status and future expectations of nanobodies in oncology trials | |
| Hernandez-Hoyos et al. | MOR209/ES414, a novel bispecific antibody targeting PSMA for the treatment of metastatic castration-resistant prostate cancer | |
| JP2020523029A5 (https=) | ||
| JP2022525435A5 (https=) | ||
| Bailly et al. | Pretargeting for imaging and therapy in oncological nuclear medicine | |
| JP2023537002A5 (https=) | ||
| IL273484B1 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
| Abousaway et al. | Noninvasive imaging of cancer immunotherapy | |
| WO2022216965A1 (en) | Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cells | |
| Guo et al. | Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment | |
| Bogen et al. | Treating bladder cancer: Engineering of current and next generation antibody-, fusion protein-, mRNA-, cell-and viral-based therapeutics | |
| JP2021517816A5 (https=) | ||
| Gao et al. | Molecular probes targeting HER2 PET/CT and their application in advanced breast cancer | |
| van Winkel et al. | Molecular imaging supports the development of multispecific cancer antibodies |